Delmar Pharma (DMPI) 0.9900 $DMPI
SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting VAL-083 Updates
ACCESSWIRE - Thu Sep 04, 8:19AM CDT
New York, NY / ACCESSWIRE / September 4, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a Q4 and FY2013 update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals to Present at the SeeThruEquity Fall Microcap Investor Conference
PR Newswire - Thu Sep 04, 7:00AM CDT
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, will be featured as a presenting company at the SeeThruEquity Fall Microcap Investor Conference. The presentation will take place at 11AM ET on September 11, 2014 at the Convene Times Square in New York City.
DelMar Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent for VAL-083
PR Newswire - Wed Sep 03, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"
today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 13/933,751, covering improved methods for synthesizing VAL-083, DelMar's lead drug candidate, which is currently in a Phase I/II clinical trial in the United States for the treatment of refractory glioblastoma multiforme (GBM). This patent is entitled "Method of Synthesis of Substituted Hexitols Such as Dianydrogalactitol," and provides a patent term that lasts until 2030.
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
PR Newswire - Fri Aug 29, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company" today announced the filing of June 30, 2014 fiscal year-end financial statements. The Company recently changed its fiscal year end to June 30th in order to facilitate an application to list its common stock on a national securities exchange in the timeliest manner possible.
DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference
PR Newswire - Wed Aug 27, 1:57PM CDT
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Tuesday, September 9th at 2:55 p.m. EDT in the Kennedy II Salon (4th floor) at the New York Palace Hotel in New York City. The presentation can be viewed live via webcast at http://wsw.com/webcast/rrshq24/dmpi and will be available for 90 days following the conference.
DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer
PR Newswire - Tue Aug 19, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company" announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m2 has been opened at three clinical trial sites in the United States. The company also confirmed that gross proceeds of US$2.9 million have been raised through warrant exercise in two separate closings. These funds provide sufficient working capital to fund DelMar's current operations, including its glioblastoma clinical trial, through at least December 2015.
DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial
PR Newswire - Thu Jul 24, 3:07PM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company" announced today that the company's board of directors approved a change of the company's fiscal year from December 31 to June 30. Accordingly, DelMar will file a Transition Form 10K on or before September 30, 2014.
DelMar Pharmaceuticals secures up to CAD194,000 in NRC-IRAP funding
M2 - Thu Jul 10, 7:20AM CDT
Cancer therapies company DelMar Pharmaceuticals (OTC BB
MPI) revealed on Wednesday the receipt of a non-refundable financial contribution of up to CAD194,000 from the National Research Council of Canada's Industrial Research Assistance Programme (NRC-IRAP).
DelMar Pharmaceuticals Receives Funding from the Canadian Federal Government
PR Newswire - Wed Jul 09, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP).
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
SeeThruEquity Issues 1Q 2014 Update on DelMar Pharmaceuticals, Inc. Highlighting VAL-083 Updates and Exercise of Warrants
ACCESSWIRE - Tue Jun 17, 8:02AM CDT
New York, NY / ACCESSWIRE / June 17, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 4Q 2013 update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals Gives Quarterly Shareholder Update and Announces Investor Conference Call
PR Newswire - Thu Mar 20, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" provided an update as of the quarter ended December 31, 2013 and a summary of progress toward the Company's goals for the year. DelMar also announced an investor conference call to take place today at 1 pm EDT. Details and log-in information will be posted on the website at www.delmarpharma.com in advance of the call.
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc.'s VAL-083 Clinical Trial
PR Newswire - Thu Mar 06, 8:00AM CST
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focuses on DelMar Pharmaceuticals recent update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM).
DelMar Pharmaceuticals to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Tue Mar 04, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26th Annual ROTH Capital Conference.
DelMar Pharmaceuticals Provides Update on VAL-083 Glioblastoma Clinical Trial
PR Newswire - Wed Feb 26, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM).
Many Business Leaders Only Play The Game While Others Change The Game
PR Newswire - Tue Feb 11, 7:30AM CST
America's PremierExperts® recently showcased a group of the country's leading businesspeople from various industries who are not just "playing the game" but they are changing it.
SeeThruEquity Initiates Research Coverage on DelMar Pharmaceuticals, Inc.
PR Newswire - Mon Jan 13, 8:00AM CST
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
PR Newswire Europe - Thu Sep 19, 7:01AM CDT
-- Glioblastoma is the most common form of brain cancer, and DelMar is developing VAL-083 in the U.S. and China to treat aggressive cancers
SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting VAL-083 Updates
ACCESSWIRE - Thu Sep 04, 8:19AM CDT
New York, NY / ACCESSWIRE / September 4, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a Q4 and FY2013 update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals to Present at the SeeThruEquity Fall Microcap Investor Conference
PR Newswire - Thu Sep 04, 7:00AM CDT
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, will be featured as a presenting company at the SeeThruEquity Fall Microcap Investor Conference. The presentation will take place at 11AM ET on September 11, 2014 at the Convene Times Square in New York City.
DelMar Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent for VAL-083
PR Newswire - Wed Sep 03, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"
today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 13/933,751, covering improved methods for synthesizing VAL-083, DelMar's lead drug candidate, which is currently in a Phase I/II clinical trial in the United States for the treatment of refractory glioblastoma multiforme (GBM). This patent is entitled "Method of Synthesis of Substituted Hexitols Such as Dianydrogalactitol," and provides a patent term that lasts until 2030. DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
PR Newswire - Fri Aug 29, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company"
today announced the filing of June 30, 2014 fiscal year-end financial statements. The Company recently changed its fiscal year end to June 30th in order to facilitate an application to list its common stock on a national securities exchange in the timeliest manner possible. DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference
PR Newswire - Wed Aug 27, 1:57PM CDT
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Tuesday, September 9th at 2:55 p.m. EDT in the Kennedy II Salon (4th floor) at the New York Palace Hotel in New York City. The presentation can be viewed live via webcast at http://wsw.com/webcast/rrshq24/dmpi and will be available for 90 days following the conference.
DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer
PR Newswire - Tue Aug 19, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company"
announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m2 has been opened at three clinical trial sites in the United States. The company also confirmed that gross proceeds of US$2.9 million have been raised through warrant exercise in two separate closings. These funds provide sufficient working capital to fund DelMar's current operations, including its glioblastoma clinical trial, through at least December 2015. DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial
PR Newswire - Thu Jul 24, 3:07PM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company"
announced today that the company's board of directors approved a change of the company's fiscal year from December 31 to June 30. Accordingly, DelMar will file a Transition Form 10K on or before September 30, 2014. DelMar Pharmaceuticals secures up to CAD194,000 in NRC-IRAP funding
M2 - Thu Jul 10, 7:20AM CDT
Cancer therapies company DelMar Pharmaceuticals (OTC BB
MPI) revealed on Wednesday the receipt of a non-refundable financial contribution of up to CAD194,000 from the National Research Council of Canada's Industrial Research Assistance Programme (NRC-IRAP). DelMar Pharmaceuticals Receives Funding from the Canadian Federal Government
PR Newswire - Wed Jul 09, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"
announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
SeeThruEquity Issues 1Q 2014 Update on DelMar Pharmaceuticals, Inc. Highlighting VAL-083 Updates and Exercise of Warrants
ACCESSWIRE - Tue Jun 17, 8:02AM CDT
New York, NY / ACCESSWIRE / June 17, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 4Q 2013 update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals Gives Quarterly Shareholder Update and Announces Investor Conference Call
PR Newswire - Thu Mar 20, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
provided an update as of the quarter ended December 31, 2013 and a summary of progress toward the Company's goals for the year. DelMar also announced an investor conference call to take place today at 1 pm EDT. Details and log-in information will be posted on the website at www.delmarpharma.com in advance of the call. SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc.'s VAL-083 Clinical Trial
PR Newswire - Thu Mar 06, 8:00AM CST
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focuses on DelMar Pharmaceuticals recent update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM).
DelMar Pharmaceuticals to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Tue Mar 04, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26th Annual ROTH Capital Conference. DelMar Pharmaceuticals Provides Update on VAL-083 Glioblastoma Clinical Trial
PR Newswire - Wed Feb 26, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM). Many Business Leaders Only Play The Game While Others Change The Game
PR Newswire - Tue Feb 11, 7:30AM CST
America's PremierExperts® recently showcased a group of the country's leading businesspeople from various industries who are not just "playing the game" but they are changing it.
SeeThruEquity Initiates Research Coverage on DelMar Pharmaceuticals, Inc.
PR Newswire - Mon Jan 13, 8:00AM CST
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
PR Newswire Europe - Thu Sep 19, 7:01AM CDT
-- Glioblastoma is the most common form of brain cancer, and DelMar is developing VAL-083 in the U.S. and China to treat aggressive cancers
